The team comprises Professors Yoshiki SAWA and Shigemi MIYAGAWA from the Cardiovascular Surgery Department of Osaka University, Dept. of Medicine. The study will be done with cell sheets from cardiomyocytes generated from iPS cells of each of the 3 patients considered. Compared with the myoblast sheets offered by Terumo Co. and derived from the patient’s thigh (“HeartSheet”), iPS cell-derived cardiomyocytes may show better exercise tolerance and improved life prognosis, as suggested from minipig experiments.
Nikkei Biotech news release, July 26, 2017